Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC

NCT04142060 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

34

Enrollment

OTHER

Sponsor class

Stopped Lack of effectiveness

Conditions

Breast Cancer

Interventions

DRUG: Enzalutamide

Sponsor

SOLTI Breast Cancer Research Group